Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)-Reference-Cited by-同舟云学术

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)

Published:2014-04-19 Issue:9 Volume:73 Page:1689-1694
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Kavanaugh Arthur,McInnes Iain B,Mease Philip,Krueger Gerald G,Gladman Dafna,van der Heijde Désirée,Zhou Yiying,Lu Jiandong,Leu Jocelyn H,Goldstein Neil,Beutler Anna

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference11 articles.

1. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT);Antoni;Arthritis Rheum,2005

2. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT);Antoni;J Rheumatol,2008

3. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial;Mease;Arthritis Rheum,2005

4. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial;Mease;Lancet,2000

5. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression;Mease;Arthritis Rheum,2004

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Summary of Certolizumab Pegol in Psoriasis Including Structural Features, Pharmacokinetics and Treatment;Immunotherapy;2024-02-06

2. Patients with longstanding psoriatic arthritis can achieve DAPSA remission or low disease activity and it correlates to better functional outcomes: results from a Latin-American real-life cohort;Advances in Rheumatology;2024-01-02

3. Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis;Clinical Rheumatology;2023-09-26

4. Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies;RMD Open;2023-09

5. Pathogenesis, multi-omics research, and clinical treatment of psoriasis;Journal of Autoimmunity;2022-12